Skip to main navigation

About
Research & Development
Pipeline
Investors
Careers

Press Releases

Press Releases

Year

July 6, 2020

Revolution Medicines Announces Proposed Public Offering of Common Stock

June 30, 2020

Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus

June 22, 2020

Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies

June 22, 2020

Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor

June 18, 2020

Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors

June 9, 2020

Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510

May 19, 2020

Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II

May 14, 2020

Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress

April 29, 2020

Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models

March 18, 2020

Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program

Pagination

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Page 7
Current page 8
Page 9
Page 10
Page 11
Next page
Last page

Displaying 71 - 80 of 107

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2023 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063
CCPA Notice | Privacy Policy

Search Investor Relations